Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2016 12/06/2016 12/07/2016 12/08/2016 12/09/2016 Date
1.55(c) 1.53(c) 1.55(c) 1.51(c) 1.5(c) Last
148 738 77 200 98 209 148 533 92 355 Volume
+5.44% -1.29% +1.31% -2.58% -0.66% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -30,9 M
Net income 2017 -28,4 M
Finance 2017 39 976 M
Yield 2017 -
Sales 2018 1,05 M
EBIT 2018 -36,2 M
Net income 2018 -34,0 M
Debt 2018 194 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 302x
Capitalization 122 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development.It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.Its products include PLacental... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
12/06 Pluristem’s PLX-R18 Advances into Second Cohort of Dose Selection Study..
11/15 PLURISTEM THERAPEUTICS : reports 1Q loss
11/15 Pluristem Reports First Quarter Fiscal 2017 Corporate and Financial Highlight..
11/13 PLURISTEM THERAPEUTICS : Chinese investor approves $30m Pluristem investment
11/11 PLURISTEM THERAPEUTICS : Pluristems $30 Million Equity Funding Approved by Innov..
11/10 PLURISTEM THERAPEUTICS INC : Entry into a Material Definitive Agreement (form 8-..
11/10 Pluristem’s $30 Million Equity Funding Approved by Innovative Medical M..
11/07 PLURISTEM THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
11/07 Pluristem Continues to Strengthen its Position in China and Receives Key Cell..
11/02 PLURISTEM THERAPEUTICS : Pluristems Pivotal Phase III Critical Limb Ischemia Tri..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
10/31 WEEK IN REVIEW : China Resources Pharma Stages $1.8 Billion Hong Kong IPO
10/26 PAST, PRESENT, AND FUTURE : Biotech, Clinton, And 2017
10/25 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
09/12 Pluristem Therapeutics net loss improves in FY16
09/12 Pluristem Therapeutics beats by $0.01, revenue in-line
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,25 $
Spread / Average Target 117%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Zami Aberman Chairman & Chief Executive Officer
Yaky Yanay President, COO, CFO, Secretary & Director
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
Mark S. Germain Director
Nachum Rosman Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS..32.74%122
QUINTILES IMS HOLDINGS..14.10%19 286
INCYTE CORPORATION-7.21%18 957
CELLTRION, INC.--.--%9 997
LONZA GROUP AG9.20%9 261
SEATTLE GENETICS, INC.44.54%9 183
More Results